Risperidone is the workhorse SGA. It is the most commonly prescribed atypical, has the broadest FDA indication set in the class, and is available in oral, ODT, oral solution, and long-acting injectable formulations. The clinical reach is enormous. Two specific features shape its profile: the dose-dependent EPS relationship and the prolactin elevation.
- Class
- Second-generation antipsychotic
- Mechanism
- D2 + 5-HT2A antagonism; also alpha-1, alpha-2, H1 antagonism. Higher D2 affinity than other SGAs → more dose-dependent EPS and prolactin.
- Typical dose
- 0.5-8 mg/day (schizophrenia typically 2-6 mg); LAI (Risperdal Consta) 12.5-50 mg IM every 2 weeks
- Half-life
- ~3 hours (parent); active metabolite paliperidone ~24 hours
- FDA indications
- Schizophrenia, bipolar mania, irritability in autism, behavioral disturbances in dementia (off-label, with caution)
- Key adverse effects
- EPS (dose-dependent, more above 6 mg), hyperprolactinemia (highest among SGAs along with paliperidone), weight gain (moderate), sedation, orthostasis
Black box: Increased mortality in elderly patients with dementia-related psychosis
Most commonly prescribed SGA. Available as oral, ODT, oral solution, and LAI. High prolactin elevation can cause sexual dysfunction, galactorrhea, menstrual disturbance — sometimes requires switching agent.
The pharmacology is high-affinity D2 antagonism combined with 5-HT2A antagonism, plus alpha-1, alpha-2, and H1 effects. Among SGAs, risperidone has the highest D2 affinity, which is what produces the dose-dependent EPS pattern. Below 4 milligrams a day, EPS is uncommon. Between 4 and 6, it rises. Above 6, risperidone approaches FGA-territory EPS. The sweet spot for most patients is 2-4 milligrams; above 6 milligrams should be a deliberate decision with EPS monitoring.
Risperidone is a potent D2/5-HT2A antagonist whose defining trait is dose-dependent behavior — atypical at low doses, increasingly FGA-like as the dose rises.
Mechanism note: Risperidone is effective but loses its atypical character at higher doses and produces the most prolactin elevation of the SGAs — both dose- and mechanism-driven liabilities to anticipate.
Prolactin elevation is among the highest in the SGA class — risperidone and its active metabolite paliperidone share this profile. Clinical manifestations: sexual dysfunction, galactorrhea, menstrual irregularity, gynecomastia. For the patient who develops these symptoms, options include switching to a prolactin-sparing SGA (aripiprazole, quetiapine), reducing dose if possible, or adding low-dose aripiprazole as a prolactin-lowering adjunct.
Weight gain is moderate — less than olanzapine, more than aripiprazole. Sedation is moderate. The metabolic profile sits in the middle of the SGA spectrum.
Risperidone has FDA approvals for schizophrenia, bipolar mania, and irritability in autism (the only SGA with a pediatric autism indication). The breadth is notable. Risperidone Consta — the long-acting injectable — is dosed every two weeks IM, providing adherence support comparable to other LAIs but with shorter intervals than paliperidone palmitate.
- Cost
- Oral generic: ~$10-30/month. Consta LAI ~$1,000-1,500/dose (every 2 weeks). Perseris (monthly SC) ~$1,800/dose.
- Generic status
- Oral generic since 2008.
- Formulary typical
- Oral generic: Tier 1-2. LAI formulations: specialty tier with PA.
- Access friction
- Oral easy. LAIs require pharmacy benefit navigation, often specialty pharmacy, sometimes buy-and-bill at clinic.
Prescriber tip: Oral risperidone is one of the cheapest effective SGAs. For LAI, Janssen patient support helps with insurance navigation. Consta's every-2-weeks frequency is logistical drag vs paliperidone monthly.
For the patient who needs a reliable, broadly indicated SGA and whose dose can stay in the lower range, risperidone is often the right choice. For the patient who needs more than 4 mg or who develops prolactin symptoms, a different agent serves better.